A Phase III, Randomized, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy.
What is the purpose of this trial?
To determine the efficacy by progression free survival (using blinded independent central
review according to modified RECIST 1.1) of olaparib maintenance monotherapy compared
to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical
complete response or partial response following first line platinum based chemotherapy.
- Astra Zeneca, L.P.
- Last Updated:
- Study HIC#: